Telomerase: Central regulator of all of the hallmarks of cancer

Trends in Biochemical Sciences

Volumn 38, Issue 9, 2013, Pages 426-434

  Low, Kee Chung ^a   Tergaonkar, Vinay ^a,b  

^a INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Apoptosis; Cancer; HTERT; Signaling; Telomere

Indexed keywords

BETA CATENIN; BETA RUBRAMYCIN; BIBR 1532; EPIDERMAL GROWTH FACTOR RECEPTOR; IMETELSTAT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 8; MICRORNA; MICRORNA 138; MICRORNA 196B; MST 312; MYC PROTEIN; N,N' BIS [2 (1 PIPERIDINO)ETHYL] 3,4,9,10 TETRACARBOXYLIC DIIMIDE; SMALL INTERFERING RNA; STAT3 PROTEIN; TELOMERASE; TELOMERASE INHIBITOR; TELOMERASE REVERSE TRANSCRIPTASE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; WNT PROTEIN; ZIDOVUDINE;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BETA CATENIN GENE; BRG 1 GENE; CANCER CELL; CANCER GROWTH; CARCINOGENESIS; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CELL TRANSFORMATION; DRUG TARGETING; ENERGY METABOLISM; ENZYME ACTIVITY; ENZYME REACTIVATION; GENE; GENETIC STABILITY; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; INFLAMMATION; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TELOMERE; TELOMERE HOMEOSTASIS; TRANSCRIPTION REGULATION; TUMOR INVASION; WNT GENE; XENOPUS LAEVIS;

APOPTOSIS; CANCER; HTERT; SIGNALING; TELOMERE;

ANIMALS; BETA CAROTENE; HUMANS; NEOPLASMS; NF-KAPPA B; SIGNAL TRANSDUCTION; TELOMERASE;

EID: 84883163849     PISSN: 09680004     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibs.2013.07.001     Document Type: Review

References (100)

1. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
2. Harley C.B., et al. Telomeres shorten during ageing of human fibroblasts. Nature 1990, 345:458-460.
3. Verdun R.E., Karlseder J. Replication and protection of telomeres. Nature 2007, 447:924-931.
4. de Lange T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev. 2005, 19:2100-2110.
5. Hayflick L. The limited in vitro lifetime of human diploid cell strains. Exp. Cell Res. 1965, 37:614-636.
6. Blackburn E.H. The end of the (DNA) line. Nat. Struct. Biol. 2000, 7:847-850.
7. Shay J.W., Bacchetti S. A survey of telomerase activity in human cancer. Eur. J. Cancer 1997, 33:787-791.
8. Vulliamy T., et al. Mutations in the telomerase component NHP2 cause the premature ageing syndrome dyskeratosis congenita. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:8073-8078.
9. Venteicher A.S., et al. Identification of ATPases pontin and reptin as telomerase components essential for holoenzyme assembly. Cell 2008, 132:945-957.
10. Wright W.E., et al. Telomerase activity in human germline and embryonic tissues and cells. Dev. Genet. 1996, 18:173-179.
11. Greenberg R.A., et al. Telomerase reverse transcriptase gene is a direct target of c-Myc but is not functionally equivalent in cellular transformation. Oncogene 1999, 18:1219-1226.
12. Yin L., et al. NF-kappa B regulates transcription of the mouse telomerase catalytic subunit. J. Biol. Chem. 2000, 275:36671-36675.
13. Zhang Y., et al. Human telomerase reverse transcriptase (hTERT) is a novel target of the Wnt/beta-catenin pathway in human cancer. J. Biol. Chem. 2012, 287:32494-32511.
14. Gizard F., et al. Telomerase activation in atherosclerosis and induction of telomerase reverse transcriptase expression by inflammatory stimuli in macrophages. Arterioscler. Thromb. Vasc. Biol. 2011, 31:245-252.
15. Mitchell J.R., et al. A telomerase component is defective in the human disease dyskeratosis congenita. Nature 1999, 402:551-555.
16. Shkreli M., et al. Reversible cell-cycle entry in adult kidney podocytes through regulated control of telomerase and Wnt signaling. Nat. Med. 2012, 18:111-119.
17. Ghosh A., et al. Telomerase directly regulates NF-kappaB-dependent transcription. Nat. Cell Biol. 2012, 14:1270-1281.
18. Broccoli D., et al. Telomerase activation in mouse mammary tumors: lack of detectable telomere shortening and evidence for regulation of telomerase RNA with cell proliferation. Mol. Cell. Biol. 1996, 16:3765-3772.
19. Bednarek A., et al. Increased telomerase activity in mouse skin premalignant progression. Cancer Res. 1995, 55:4566-4569.
20. Artandi S.E., et al. Constitutive telomerase expression promotes mammary carcinomas in aging mice. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:8191-8196.
21. Gonzalez-Suarez E., et al. Increased epidermal tumors and increased skin wound healing in transgenic mice overexpressing the catalytic subunit of telomerase, mTERT, in basal keratinocytes. EMBO J. 2001, 20:2619-2630.
22. Sarin K.Y., et al. Conditional telomerase induction causes proliferation of hair follicle stem cells. Nature 2005, 436:1048-1052.
23. Canela A., et al. Constitutive expression of tert in thymocytes leads to increased incidence and dissemination of T-cell lymphoma in Lck-Tert mice. Mol. Cell. Biol. 2004, 24:4275-4293.
24. Stewart S.A., et al. Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:12606-12611.
25. Bryan T.M., Reddel R.R. Telomere dynamics and telomerase activity in in vitro immortalised human cells. Eur. J. Cancer 1997, 33:767-773.
26. Li S., et al. Rapid inhibition of cancer cell growth induced by lentiviral delivery and expression of mutant-template telomerase RNA and anti-telomerase short-interfering RNA. Cancer Res. 2004, 64:4833-4840.
27. Maida Y., et al. An RNA-dependent RNA polymerase formed by TERT and the RMRP RNA. Nature 2009, 461:230-235.
28. Montanaro L., et al. Novel dyskerin-mediated mechanism of p53 inactivation through defective mRNA translation. Cancer Res. 2010, 70:4767-4777.
29. Huber O., et al. Pontin and reptin, two related ATPases with multiple roles in cancer. Cancer Res. 2008, 68:6873-6876.
30. Choi J., et al. TERT promotes epithelial proliferation through transcriptional control of a Myc- and Wnt-related developmental program. PLoS Genet. 2008, 4:e10.
31. Park J.I., et al. Telomerase modulates Wnt signalling by association with target gene chromatin. Nature 2009, 460:66-72.
32. Ang H.L., Tergaonkar V. Notch and NFkappaB signaling pathways: Do they collaborate in normal vertebrate brain development and function?. Bioessays 2007, 29:1039-1047.
33. Fragoso M.A., et al. The Wnt/beta-catenin pathway cross-talks with STAT3 signaling to regulate survival of retinal pigment epithelium cells. PLoS ONE 2012, 7:e46892.
34. Smith L.L., et al. Telomerase modulates expression of growth-controlling genes and enhances cell proliferation. Nat. Cell Biol. 2003, 5:474-479.
35. Hrdličková R., et al. Alternatively spliced telomerase reverse transcriptase variants lacking telomerase activity stimulate cell proliferation. Mol. Cell. Biol. 2012, 32:4283-4296.
36. Lindvall C., et al. Molecular characterization of human telomerase reverse transcriptase-immortalized human fibroblasts by gene expression profiling: activation of the epiregulin gene. Cancer Res. 2003, 63:1743-1747.
37. Inatomi O., et al. Regulation of amphiregulin and epiregulin expression in human colonic subepithelial myofibroblasts. Int. J. Mol. Med. 2006, 18:497-503.
38. Fynan T.M., Reiss M. Resistance to inhibition of cell growth by transforming growth factor-beta and its role in oncogenesis. Crit. Rev. Oncog. 1993, 4:493-540.
39. Stampfer M.R., et al. Expression of the telomerase catalytic subunit, hTERT, induces resistance to transforming growth factor beta growth inhibition in p16INK4A(-) human mammary epithelial cells. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:4498-4503.
40. Geserick C., et al. Expression of mTert in primary murine cells links the growth-promoting effects of telomerase to transforming growth factor-beta signaling. Oncogene 2006, 25:4310-4319.
41. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
42. Kinzler K.W., Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996, 87:159-170.
43. Zhou Z.Q., Hurlin P.J. The interplay between Mad and Myc in proliferation and differentiation. Trends Cell Biol. 2001, 11:S10-S14.
44. Yochum G.S., et al. A genome-wide screen for beta-catenin binding sites identifies a downstream enhancer element that controls c-Myc gene expression. Mol. Cell. Biol. 2008, 28:7368-7379.
45. Beck S., et al. Telomerase activity-independent function of TERT allows glioma cells to attain cancer stem cell characteristics by inducing EGFR expression. Mol. Cells 2011, 31:9-15.
46. Falchetti M.L., et al. Inhibition of telomerase in the endothelial cells disrupts tumor angiogenesis in glioblastoma xenografts. Int. J. Cancer 2008, 122:1236-1242.
47. George J., et al. Combination of hTERT knockdown and IFN-gamma treatment inhibited angiogenesis and tumor progression in glioblastoma. Clin. Cancer Res. 2009, 15:7186-7195.
48. Lee S.H., et al. IFN-gamma/IRF-1-induced p27kip1 down-regulates telomerase activity and human telomerase reverse transcriptase expression in human cervical cancer. FEBS Lett. 2005, 579:1027-1033.
49. Zhou L., et al. Telomerase reverse transcriptase activates the expression of vascular endothelial growth factor independent of telomerase activity. Biochem. Biophys. Res. Commun. 2009, 386:739-743.
50. Zaccagnini G., et al. Telomerase mediates vascular endothelial growth factor-dependent responsiveness in a rat model of hind limb ischemia. J. Biol. Chem. 2005, 280:14790-14798.
51. Bermudez Y., et al. VEGF- and LPA-induced telomerase in human ovarian cancer cells is Sp1-dependent. Gynecol. Oncol. 2007, 106:526-537.
52. Irelan J.T., et al. A role for IkappaB kinase 2 in bipolar spindle assembly. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:16940-16945.
53. Singhapol C., et al. Mitochondrial telomerase protects cancer cells from nuclear DNA damage and apoptosis. PLoS ONE 2013, 8:e52989.
54. Bermudez Y., et al. Telomerase confers resistance to caspase-mediated apoptosis. Clin. Interv. Aging 2006, 1:155-167.
55. Cao Y., et al. TERT regulates cell survival independent of telomerase enzymatic activity. Oncogene 2002, 21:3130-3138.
56. Indran I.R., et al. hTERT overexpression alleviates intracellular ROS production, improves mitochondrial function, and inhibits ROS-mediated apoptosis in cancer cells. Cancer Res. 2011, 71:266-276.
57. Liu Z., et al. Telomerase reverse transcriptase promotes epithelial-mesenchymal transition and stem cell-like traits in cancer cells. Oncogene 2012, 10.1038/onc.2012.441.
58. Huber M.A., et al. NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J. Clin. Invest. 2004, 114:569-581.
59. Fukuyama R., et al. Role of IKK and oscillatory NFkappaB kinetics in MMP-9 gene expression and chemoresistance to 5-fluorouracil in RKO colorectal cancer cells. Mol. Carcinog. 2007, 46:402-413.
60. Wei L.H., et al. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene 2003, 22:1517-1527.
61. Becker C., et al. IL-6 signaling promotes tumor growth in colorectal cancer. Cell Cycle 2005, 4:217-220.
62. Grivennikov S., et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009, 15:103-113.
63. Gilbert L.A., Hemann M.T. DNA damage-mediated induction of a chemoresistant niche. Cell 2010, 143:355-366.
64. Wu S., et al. Targeted blockade of interleukin-8 abrogates its promotion of cervical cancer growth and metastasis. Mol. Cell. Biochem. 2013, 375:69-79.
65. Shao N., et al. The depletion of interleukin-8 causes cell cycle arrest and increases the efficacy of docetaxel in breast cancer cells. Biochem. Biophys. Res. Commun. 2013, 431:535-541.
66. Sethi G., et al. TNF: a master switch for inflammation to cancer. Front. Biosci. 2008, 13:5094-5107.
67. Mantovani A., et al. Cancer-related inflammation. Nature 2008, 454:436-444.
68. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
69. Balkwill F.R., Mantovani A. Cancer-related inflammation: common themes and therapeutic opportunities. Semin. Cancer Biol. 2012, 22:33-40.
70. Kanterman J., et al. New insights into chronic inflammation-induced immunosuppression. Semin. Cancer Biol. 2012, 22:307-318.
71. Baniyash M. Chronic inflammation, immunosuppression and cancer: new insights and outlook. Semin. Cancer Biol. 2006, 16:80-88.
72. Biswas S.K., Tergaonkar V. Myeloid differentiation factor 88-independent Toll-like receptor pathway: Sustaining inflammation or promoting tolerance?. Int. J. Biochem. Cell Biol. 2007, 39:1582-1592.
73. Tilg H., et al. IL-6 and APPs: anti-inflammatory and immunosuppressive mediators. Immunol. Today 1997, 18:428-432.
74. Perkins N.D., Gilmore T.D. Good cop, bad cop: the different faces of NF-kappaB. Cell Death Differ. 2006, 13:759-772.
75. Perkins N.D. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat. Rev. Mol. Cell Biol. 2007, 8:49-62.
76. Bagheri S., et al. Genes and pathways downstream of telomerase in melanoma metastasis. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:11306-11311.
77. Morrish F., et al. The oncogene c-Myc coordinates regulation of metabolic networks to enable rapid cell cycle entry. Cell Cycle 2008, 7:1054-1066.
78. Yeung S.J., et al. Roles of p53, MYC and HIF-1 in regulating glycolysis - the seventh hallmark of cancer. Cell. Mol. Life Sci. 2008, 65:3981-3999.
79. Kawauchi K., et al. p53 regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation. Nat. Cell Biol. 2008, 10:611-618.
80. Artandi S.E., DePinho R.A. Telomeres and telomerase in cancer. Carcinogenesis 2010, 31:9-18.
81. Masutomi K., et al. The telomerase reverse transcriptase regulates chromatin state and DNA damage responses. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:8222-8227.
82. Zhang X., et al. Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Genes Dev. 1999, 13:2388-2399.
83. Smogorzewska A., de Lange T. Different telomere damage signaling pathways in human and mouse cells. EMBO J. 2002, 21:4338-4348.
84. Seimiya H., et al. Telomere shortening and growth inhibition of human cancer cells by novel synthetic telomerase inhibitors MST-312, MST-295, and MST-1991. Mol. Cancer Ther. 2002, 1:657-665.
85. Pascolo E., et al. Mechanism of human telomerase inhibition by BIBR1532, a synthetic, non-nucleosidic drug candidate. J. Biol. Chem. 2002, 277:15566-15572.
86. Mizushina Y., et al. Anti-cancer targeting telomerase inhibitors: beta-rubromycin and oleic acid. Mini Rev. Med. Chem. 2012, 12:1135-1143.
87. Pillich R.T., et al. The diimide drug PIPER has a cytotoxic dose-dependent effect in vitro and inhibits telomere elongation in HELA cells. Anticancer Res. 2005, 25:3341-3346.
88. Shi D.F., et al. Quadruplex-interactive agents as telomerase inhibitors: synthesis of porphyrins and structure-activity relationship for the inhibition of telomerase. J. Med. Chem. 2001, 44:4509-4523.
89. Brown T., et al. Telomerase inhibition using azidothymidine in the HT-29 colon cancer cell line. Ann. Surg. Oncol. 2003, 10:910-915.
90. Buseman C.M., et al. Is telomerase a viable target in cancer?. Mutat. Res. 2012, 730:90-97.
91. Joseph I., et al. The telomerase inhibitor imetelstat depletes cancer stem cells in breast and pancreatic cancer cell lines. Cancer Res. 2010, 70:9494-9504.
92. Li S., et al. Cellular and gene expression responses involved in the rapid growth inhibition of human cancer cells by RNA interference-mediated depletion of telomerase RNA. J. Biol. Chem. 2005, 280:23709-23717.
93. Saretzki G., et al. Ribozyme-mediated telomerase inhibition induces immediate cell loss but not telomere shortening in ovarian cancer cells. Cancer Gene Ther. 2001, 8:827-834.
94. Soriano A., et al. microRNAs as pharmacological targets in cancer. Pharmacol. Res. 2013, 10.1016/j.phrs.2013.03.006.
95. Mitomo S., et al. Downregulation of miR-138 is associated with overexpression of human telomerase reverse transcriptase protein in human anaplastic thyroid carcinoma cell lines. Cancer Sci. 2008, 99:280-286.
96. Gong H., et al. Downregulation of miR-138 sustains NF-kappaB activation and promotes lipid raft formation in esophageal squamous cell carcinoma. Clin. Cancer Res. 2013, 19:1083-1093.
97. Bhatia S., et al. Potential tumor suppressive function of miR-196b in B-cell lineage acute lymphoblastic leukemia. Mol. Cell. Biochem. 2010, 340:97-106.
98. Lai X.F., et al. PinX1 regulation of telomerase activity and apoptosis in nasopharyngeal carcinoma cells. J. Exp. Clin. Cancer Res. 2012, 31:12.
99. Inderberg-Suso E.M., et al. Widespread CD4+ T-cell reactivity to novel hTERT epitopes following vaccination of cancer patients with a single hTERT peptide GV1001. Oncoimmunology 2012, 1:670-686.
100. Su Z., et al. Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J. Immunol. 2005, 174:3798-3807.